ABOUT GAVI

Gavi’s mission: to save children’s lives and protect people’s health by increasing equitable use of vaccines in lower-income countries.
GAVI’S PARTNERSHIP MODEL

Working together to build on the comparative advantages of both public & private partners
IMPACT OF GAVI SUPPORT

Impact of Gavi’s programs: 2001-2015

- Million children immunized: 580
- Million future deaths averted*: >8
- Vaccine introductions and campaigns: >300

Accelerating & Expanding Impact: 2016-2020

- Million children immunized: 300 million
- Million lives saved: 5–6
- Million illness cases averted: >100
- US$ billion costs averted related to illness:
  - Productivity loss due to death/disability
  - Treatment costs
  - Caretaker productivity loss
  - Transport costs

* Projection
Source: Gavi, the Vaccine Alliance data as of December 2015.
THE GAVI BUSINESS MODEL

Finding innovative financing solutions to immunization challenges is at the core of the Gavi model

**Donor base**
- Securing long-term predictable financing through multi-year commitments from public & private-sector donors, leveraging capital markets, and doubling the impact of private sector funds.

**Market-shaping**
- Creating reliable markets for vaccines in developing countries by pooling demand, securing lower pricing through long-term commitments, and accelerating the development and supply of affordable vaccines.

**Co-financing**
- Countries contribute to the cost of buying their own vaccines, determined by their GNI per capita, with contributions growing until they are able to cover 100% of vaccine costs and transition from Gavi support.
DONOR CONTRIBUTIONS: US$ 7.539 BILLION MOBILISED (2016-2020)
INNOVATIVE SOLUTIONS FOR INVESTING IN HEALTH

The International Finance Facility for Immunization (IFFIm)

- Established in 2006, IFFIm was set up to rapidly accelerate the availability and predictability of funds—drawing down funds when they’re needed most—to support Gavi’s immunization programs.

- IFFIm issues bonds in the capital markets, converting the long-term pledges from donors into immediately available cash resources.

- Donor pledges, totaling US$ 6.5 billion to date, are used in part to repay IFFIm bondholders.

We encourage consideration of how existing mechanisms, such as the International Finance Facility for Immunisation, might be replicated to address broader development needs.

INNOVATIVE SOLUTIONS FOR INVESTING IN HEALTH

Advanced Market Commitment (AMC)
Generating incentives for vaccine manufactures to produce suitable and affordable vaccines for the world’s poorest countries.

Donors commit funds for new vaccines that meet stringent criteria and are requested by developing countries, at pre-agreed price

Manufacturers get incentive to invest in R&D – legally committing to supply vaccines at lower prices in the long term

Developing countries and Gavi pay long-term, lower price for the vaccines

#vaccineswork
2016-2020 PRIVATE SECTOR ENGAGEMENT APPROACH

Leverage private sector investments, expertise, and innovation to accelerate impact and develop efficient, sustainable solutions at scale

- **FINANCIAL CONTRIBUTION**
  - Single or multi-year financial pledge in support of Gavi programs that may be matched by Matching Fund
    - (e.g. corporate or foundation philanthropic support)

- **LEVERAGED INVESTMENT PARTNERSHIP**
  - Financial pledge accompanied by corporate expertise or programmatic intervention with potential match by Matching Fund
    - (e.g. awareness raising, bundled interventions)

- **SHARED VALUE PARTNERSHIP**
  - Long-term operational partnership fully integrated with Gavi model
    - (e.g. vaccine supply, cold-chain equipment, supply chain services)
MARKET SHAPING: GAVI PRICES START FROM LOW BASELINE

Gavi aims to ensure sufficient supply of appropriate, quality vaccines at low and sustainable prices.

Cost of full course of:

$35 in 2010

PENTAVALENT
HEPATITIS B
DTP
Hib
ROTAVIRUS
PNEUMOCOCCAL
POLIO IPV
MEASLES
RUBELLA
HPV

Purchasing vaccines for 60% of world’s birth cohort

Approx. USA price: US$ 950

Gavi price: US$ 35

Sources: CDC vaccine price list November 2015; UNICEF Supply Division, March 2016
CO-FINANCING: PREPARING FOR TRANSITION AND SUSTAINABILITY

**Purpose:** To enhance ownership and put countries on a trajectory towards financial sustainability to prepare for phasing out of Gavi support.

Source: Gavi, the Vaccine Alliance, 2016
Fully self-financing countries:
independently launching new vaccines, high coverage

- Bhutan (independent pneumococcal launch, June)
- Mongolia
- Honduras (co-funded HPV launch, May)
- Sri Lanka (co-funded HPV launch, date tbc)

99% penta3 coverage

PRIORITIZING INVESTMENTS IN HEALTH

- Future Outbreaks
- Long-term Sustainability
- R&D
- Fragile States
RECOMMENDATIONS FOR A NEW ADMINISTRATION

Seek impactful, long-term, flexible funding & private sector engagement

As the largest contributor toward health/development, US has a key leadership role in the global community influence both high- and middle-income countries.

• Leverage long-standing US commitment to global health to generate strong political will in other donor markets

• Encourage engagement from the private sector to help fill critical gaps and enhance capacities of health systems.

• Explore how innovative financing mechanisms (new or existing) can be used to accelerate investments in new technology and innovative approaches to solving global health problems.
THANK YOU
INVESTING IN IMMUNIZATION

Vaccines are one of the most successful and cost-effective health investments in history

- Total economic benefits expected to exceed $1.5 trillion
- 164,000 children immunized EVERY DAY through Gavi support
- Vaccinated children live longer and lead healthier, more productive lives
- 16:1 return on investment

Generate savings for health systems and families by reducing illness and long-term disability

#vaccineswork
HOW OUR SUPPORT WORKS

APPLICATIONS FOR GAVI SUPPORT

IMPLEMENTING COUNTRY PROPOSAL SUBMISSION
INDEPENDENT REVIEW COMMITTEE
RECOMMENDATIONS & ISSUES TO BE ADDRESSED
GAVI BOARD APPROVAL

IMPLEMENTATION

GRANT DISBURSEMENT & VACCINE DELIVERY
ROUTINE GRANT MONITORING & REPORTING (performance frameworks, reports, evaluations, and annual in-country, multi-stakeholder review)
REVIEW & RENEWAL (approve renewals and respond to technical assistance needs)
GAVI’S STRATEGIC GOALS 2016–2020

- Accelerate equitable uptake and coverage of vaccines
- Increase effectiveness & efficiency of immunization delivery as integrated part of strengthened health systems
- Shape markets for vaccines and other immunization products
- Improve sustainability of national immunization programs
BEYOND CO-FINANCING NEW VACCINES

Increasing domestic expenditure on immunisation

Gavi co-financing

- 2011-2015: US$ 0.47 billion
- 2016-2020: US$ 1.2 billion

Total domestic investments in immunisation

- 2011-2015: US$ 8 billion
- 2016-2020: US$ 12 billion

+250%